Cargando…
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Patients require frequent surgical debridement of disease, and no approved systemi...
Autores principales: | Allen, Clint T., Lee, Sunmin, Norberg, Scott M., Kovalovsky, Damian, Ye, Hong, Clavijo, Paul E., Hu-Lieskovan, Siwen, Schlegel, Richard, Schlom, Jeffrey, Strauss, Julius, Gulley, James L., Trepel, Jane, Hinrichs, Christian S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500000/ https://www.ncbi.nlm.nih.gov/pubmed/31053174 http://dx.doi.org/10.1186/s40425-019-0603-3 |
Ejemplares similares
-
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021) -
Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022) -
Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes
por: Sievers, Cem, et al.
Publicado: (2021) -
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
por: Lee, Maxwell Y., et al.
Publicado: (2021) -
Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)